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Opinion
Vaccination against Allergy: A Paradigm Shift?Martin F. Bachmann,1,2 Mona O. Mohsen,2,3 Matthias F. Kramer,4,5,6 and Matthew D. Heath4,6,*Highlights
Recent advances in the use of virus-like
particle (VLP) nanotechnology provides
an optimal strategy for the treatment of
allergy; eliminating the allergic potential
of a vaccine while increasing its ability to
trigger strong IgG reactions.
Modern approaches to allergen-specific
immunotherapy (SIT) exploiting ad-
vances in antigen carrier systems such
as VLP, aimed at maximizing IgG-
mediated inhibition of allergen-induced
mast cell activation, present a paradigm
shift toward using a classical vaccinationSince the discovery that IgE antibodies mediate allergy, decades of research
have unraveled complex mechanisms associated with conventional immuno-
therapy and the vital protagonists that shape ‘immune tolerance’ to allergens.
Debate exists on what should constitute the dominant effector mechanism in
driving rational drug designs for next-generation immunotherapies. As vaccine
technology continues to advance, the development of novel vaccines in this
area of continued medical need might stand on a threshold of breakthrough in-
spired by experiments by Dunbar on the passive vaccination of allergic animals
more than 100 years ago. In this opinion article, we discuss both novel insights
into IgG antibodies as the principle effector modality induced by specific immu-
notherapy and advances in antigen-carrier design that may catapult allergy treat-
ment into our modern world.approach to treat allergy.
The translational potential of VLP tech-
nology in allergy may eventually be useful
for prophylactic vaccination.
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com (M.D. Heath).Allergy: From Orphan Disease to Pandemic
Allergic rhinitis, allergic asthma, and food allergies (see Glossary) are recently burgeoning
diseases. The first documented case of hay fever occurred in 1819, when the physician, John
Bostock, called the disease catarrhus aestivus (summer catarrh) [1]. Given that Bostock had
the disease himself, this first patient was easily found; it took himmore than 9 years to find another
28 cases, clearly demonstrating the scarcity of the disease rather than absence of reporting [2].
This has since dramatically changed and IgE-mediated allergies, such as allergic rhino conjunc-
tivitis and asthma, have reached a worldwide prevalence of 25% [3], followed by food allergy, with
a prevalence of ~10% [4]. Together with type 2 diabetes mellitus, they are called ‘the new epi-
demics of the 21st century’ [5]. This increase in prevalence is still rather poorly understood but
evidence indicates a correlation with improved hygiene, altered nutrition, or reduced viral, bacte-
rial, or parasitic diversity, or, more likely, it is a result of a complex interplay of all of these factors,
summarized as the ‘biodiversity hypothesis’ [6]. In addition, epigenetic changes may additionally
regulate the risk of developing allergies [7].
Potential Treatment for Allergies: From Symptomatic to Disease-Modifying
Therapies
There are several ways to treat IgE-mediated allergies. The most accessible and commonly used
therapies are symptomatic in nature and block the allergic reactions at the effector stage by
inhibiting the action of histamine by using corticosteroids. While these therapies are effective,
they usually need daily drug intake, which is not without chronic adverse effects if taken for
years, and, most importantly, does not stop progression of the disease toward, for example,
asthma. By contrast, allergen-specific immunotherapy (SIT) is the only disease-modifying
therapy available [8,9]. SIT comprises repeated administration of specific allergens to patients
with IgE-mediated allergies and results in protection against the allergic and inflammatory reac-
tions usually associated with natural exposure to the same allergens [8]. The efficacy of SIT
only recently became scientifically accepted subsequent to appropriate state-of-the-art double-
blind, placebo-controlled trials. Indeed, it is now an established andmedically preferred treatment
option against respiratory allergies and hymenopteran venom allergy [8–11].Trends in Molecular Medicine, April 2020, Vol. 26, No. 4 https://doi.org/10.1016/j.molmed.2020.01.007 357
© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Glossary
Adjuvant: a substance that enhances
the immune-stimulating properties of an
antigen or the pharmacological effect of
a drug.
Allergen-specific immunotherapy
(SIT): also known as desensitization or
hyposensitization; the most common
form of specific immunotherapy;
involves a course of injections that build
up tolerance to particular allergens
through small, controlled doses.
Allergens: proteins that trigger the
immune system of an allergic person to
produce unwanted symptoms.
Allergy: a chronic condition involving an
exaggerated reaction to an otherwise
harmless substance, called an allergen.
B cells: differentiate into clones of
antibody-producing plasma cells; have a
central role in allergen tolerance through
the production of IgG-blocking
antibodies.
CpG: oligonucleotides enriched in CpG
motifs are potent immunopotentiators of
dendritic cells and B cells.
FcƐRI: a high-affinity IgE receptor
expressed on the cell surface of mast
cells and basophils; triggers the IgE-
mediated allergic cascade.
FcγRIIb: a low-affinity IgG receptor. IgG
antibodies can inhibit IgE-mediated
mast cell activation through direct
allergen neutralization or through the
inhibitory receptor FcγRIIb.
IgE: primary antibody mediator in the
allergic response.
IgG: most common antibody in the
body; used to treat a range of diseases.
Mast cells: similar to basophils, mast
cells become activated by antigen
crosslinking of FcƐRI receptor-bound
IgE to undergo rapid degranulation and
release of the inflammatory substance
histamine, causing an allergic reaction.
Microcrystalline tyrosine (MCT): a
depot adjuvant.
Pathogen-associated structural
pattern (PASP): a pathogen-
associated molecular pattern (PAMP).
Cells of the innate immune system utilize
pattern recognition receptors to identify
viral pathogens by engaging PAMPs.
Regulatory T cells (Tregs): involved in
preventing sensitization to allergens by
suppression of T cell responses to T cell
epitopes of major allergens.
Thelper (Th) cell: also known asCD4+
cells; a type of T cell that help the activity
of other immune cells by releasing T cell
cytokines. These cells help suppress or
regulate immune responses. For
Trends in Molecular MedicineDespite the clinical success of SIT, conventional long-course subcutaneous immunotherapy, typi-
cally formulated with an aluminum depot, remains cumbersome (e.g., monthly injections over
3 years) and themechanisms of action remains unclear. To date, there are no validated and generally
accepted candidate biomarkers that are predictive or indicative of the clinical response to conven-
tional SIT [12]. It is recommended to explore the use of allergen-specific IgG4 as a biomarker for
compliance. Serum IgE/total IgE and IgE-facilitated allergen binding (FAB) are considered as poten-
tial surrogate candidate biomarkers, although induction of increased type 1 T helper cells (Th1), in
particular regulatory T cells (Tregs), has been postulated tomediate clinical efficacy [12]. More re-
cently, additional immune cells, such as innate-like lymphocytes (ILCs) [13] and regulatory B cells
[14,15], have also been implicated in SIT. However, in the absence of a clear effector mechanism,
optimizing the therapy remains largely empirical and the primary endpoint in trials is based on sub-
jective combined symptom and medication scores. Nevertheless, adjuvant systems, such asmi-
crocrystalline tyrosine (MCT) combined with monophosphoryl lipid A (MPL) [16–21] or CpGs
(DNA rich in non-methylated CG motifs, a ligand for TLR9) in free form [22] or packaged into
virus-like particles (VLPs) [23,24], have been tailored in formulations that have achieved evi-
dence of efficacy in fewer doses comparedwith conventional treatments andmay offer newoppor-
tunities in identifying novel biomarker candidates. Formulating the allergens with depot adjuvants or
the use of allergoids, which exhibit chemically modified epitopes, are also ways to increase the
dose but maintain tolerability [24,25]. Several novel approaches to develop next-generation aller-
gen immunotherapies have been further explored. Such approaches include novel microbiome ap-
plications, peptide immunotherapy, intralymphatic immunotherapy, epicutaneous immunotherapy,
and the use of nanoparticles with or without native allergens [23,24,27–30].
Many lessons may be drawn from the successes in vaccinology; thanks to new technologies,
vaccines are on a path to revolutionize the health of the modern population [31,32]. More than
100 years ago, allergen immunotherapy was described in a way that drew parallels with
vaccinology at this time, described as ‘a prophylactic vaccination against hay fever’ [33]. Upon
the discovery of IgE and research to further elucidate the rather complex interplay of immunolog-
ical mechanisms that mediate allergy and conventional SIT, those fundamental parallels with
vaccinology (‘a vaccine against toxins’) were somewhat lost and subsequent research focused
on the idea that SIT should ‘induce tolerance’, dampening IgE reactivity [34]. However, the design
of several new technology platforms has revived the concept that allergens may be viewed as
‘protoxins’, highlighting the importance and protective umbrella of neutralizing antibodies,
which is now considered to be broader than first appreciated [34,35].
Here, we discuss allergen-specific IgG antibodies, which may be considered a key effector mo-
dality in SIT; allergens displayed on VLP, which are highly immunogenic but do not induce ana-
phylactic reactions; the induction of IgG antibodies against a single allergen combined with VLP
nanoparticles to protect against a complex allergen cocktail. The growing evidence in using ad-
vanced nanoparticle technology reviewed herein considers a paradigm shift toward a classical
vaccination approach to treat allergy (see Clinician’s Corner).
Allergen-Specific IgG Antibodies Are the Key Effector Modality in SIT
SIT induces a change in T cell subtypes,mainly Tregs and a shift from type 2 T helper cells (Th2)
to Th1 cells [36,37]. While induction of Tregs appears to be transient, a reduction in Th2 cell ac-
tivity is more long-lasting [38]. Both Th1 and Tregs are thought to block Th2 cells, causing a non-
allergic milieu and depletion of IgE synthesis in the long term (Figure 1A). In addition to a change in
T cells, SIT induces allergen-specific IgE and IgG. Allergen-specific IgG production may often de-
pend on the induction of regulatory B cells, which also secrete immune-suppressive cytokines
[14,15].358 Trends in Molecular Medicine, April 2020, Vol. 26, No. 4
example, they are essential in B cell
antibody class switching.
Type 1 T helper cells (Th1): mediate
cell-mediated immune responses to
intracellular pathogens, such as viruses,
bacteria, or tumor antigens.
Type 2 T helper cells (Th2): allergen-
specific Th2 responses have a pivotal
role in the activation and/or recruitment
of IgE antibody-producing B cells, mast
cells, and eosinophils.
Virus-like particles (VLPs):molecules
that closely resemble viruses, but are
non-infectious because they contain no
viral genetic material. They can be
naturally occurring or synthesized
through the individual expression of viral
structural proteins, which can then self-
assemble into the virus-like structure.
Trends in Molecular Medicine
Figure 1. Kinetic Considerations in the Regulation of Allergic Responses. (A) Type 2 T helper cells (Th2) enhance the
activation of an IgE-mediated allergic response. Regulatory T cells (Tregs) inhibit IgE production indirectly via inhibiting Th2
while allergen-specific IgG directly inhibits IgE via different mechanisms. (B) (i). Allergens crosslink IgE molecules bound to
the surface of tissue mast cells, which rapidly triggers degranulation and the release of preformed mediators, including
histamine, within minutes. (ii) Antigen uptake and processing by dendritic cells for T cell activation requires hours rathe
than minutes, which presents a kinetic disadvantage. (iii) Allergen-specific IgG are able to bind and block allergen-induced
cellular activation within seconds.
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Onemillion-foldmore IgG than IgE (milligrams per milliliter versus nanograms per milliliter) circulate
in the bloodstream, and allergens are likely to form complexes with polyclonal IgG antibodies of
several specificities before they reach FcƐRI-bound IgE [39].lecular Medicine, April 2020, Vol. 26, No. 4 359
Trends in Molecular MedicineIgG4, the least-represented human IgG subclass in serum, is an intriguing antibody with unique
biological properties, such as the ability to undergo Fab-arm exchange and to limit immune com-
plex formation. The lack of effector functions, such as antibody-dependent cell-mediated cytotox-
icity and complement-dependent cytotoxicity, is desirable for therapeutic purposes. IgG4 has a
protective role in allergy by acting as a blocking antibody (Figure 1A), and inhibitingmast cell de-
granulation [40] Furthermore, crosslinking of FcγRIIb by the IgG4 subclass redirects proallergic
M2a macrophages to an M2b-like immunosuppressive phenotype. This suggests an interplay of
macrophages with IgG4 in immune tolerance, likely relevant in allergen immunotherapy [41].
The Mechanisms of SIT Revisited: Th1 and Tregs
Allergen-specific IgE induction occurs early after treatment and is transient ,while IgG responses
are long lasting. Importantly, the increase in IgG is more prominent than the long-term reduction in
IgE levels; in addition, a reduction in IgE does not always occur [42]. Hence, the effector mecha-
nism induced by SIT must be able to block allergic responses despite the presence of allergen-
specific IgE. As discussed previously [34], this renders Tregs and Th1 cells unlikely candidates
mostly for kinetic reasons. Indeed, allergic symptoms in hay fever occur within minutes and,
therefore, cannot be blocked by antigen-specific T cells, which are activated by the recognition
of allergen-derived peptides presented on MHC class II molecules (Figure 1B). Processing aller-
gens for antigen-presentation requires hours rather than minutes, excluding sufficiently rapid ac-
tivation of T cells to block IgE-mediated mast cell or basophil activation (Figure 1B). It may be
argued that Tregs create a non-inflammatory milieu; however, such a mechanism would not be
allergen specific and, therefore, is not compatible with clinical experience [34,43,44]. In addition,
depletion of Tregs in a murine model of cat allergy did not abrogate protection induced by SIT
[45]. In contrast to slowly activated allergen-specific T cells, allergen-specific IgG may be able
to block allergen-induced cellular activation within seconds (Figure 1B).
The Mechanisms of SIT Revisited: Antibodies
It is well established that SIT induces allergen-neutralizing IgG antibodies [38,42] and that these
antibodies are able to block IgE-mediated antigen presentation. Even though induction of IgG
does not always correlate with clinical efficacy [12], the IgE:IgG ratio might be the more important
parameter yielding better correlations or, indeed, considerations related to the affinity and/or avid-
ity of IgG4 and ELISA-based approaches to establish a meaningful correlation [12]. In a classical
experiment, immune sera from patients after but not before SIT were able neutralize allergens in a
skin-prick test, directly demonstrating the therapeutic potential of allergen-specific IgG [46]. Fur-
thermore, it has been shown in murine models of cat and peanut allergies that the transfer of
allergen-specific IgG resulted protection against local and systemic allergen challenge [35,47].
An important piece of evidence for a protective role of allergen-specific IgG was recently provided
in a clinical study that demonstrated that passive vaccination with monoclonal antibodies (mAbs)
against Fel d 1, the major allergen in cats, protected humans against allergic symptoms [48].
Thus, such evidence resuscitates the concept from the early 20th century developed by the
American physician Dunbar using antibody-based immunotherapy [49,50].
IgG antibodies may block mast cell and/or basophil activation via three pathways: direct allergen
neutralization (Figure 2A); engagement of the inhibitory FcγRIIb (Figure 2B) [51]; and co-
internalization of IgE by mast cells (Figure 2C) [52]. Direct allergen neutralization is the most
straightforward mechanism, because it simply blocks the access of the allergen to IgE bound
to the high-affinity Fc RI (Figure 2A).
However, allergen neutralization is demanding since the antibodies essentially need to block all
epitopes recognized by IgE. It was recently shown that only high-affinity antibodies are able to360 Trends in Molecular Medicine, April 2020, Vol. 26, No. 4
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Figure 2. Inhibition of Mast Cell and/or Basophil Activation. IgG antibodies can block mast cell activation via three
main pathways. (A) Allergen-specific IgG antibodies can directly neutralize the allergen by forming allergen–immune
complexes and blocking their access to IgE bound to the high-affinity Fc RI. (B) Engagement of the inhibitory recepto
FcγRIIb by IgG–immune complexes blocks mast cell activation. (C) Allergen-specific IgG interacts with FcγRIIb and
promotes IgE internalization, which inhibits mast cell activation.
Trends in Molecular Medicine
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mediate allergen neutralization [35]. By contrast, engagement of the inhibitory receptor FcγRIIb by
an IgG-allergen immune complex is sufficient to block cellular activation. Hence, this mechanism
is less demanding because not all epitopes need to be targeted. Furthermore, and rather unex-
pectedly, antibodies with affinities as low as 10–7 M effectively shut down mast cell activation
[35]. Hence, in contrast to neutralizing antibodies, FcγRIIb-engaging IgG antibodies can be of
low affinity. Engagement of FcγRIIb causes its internalization and it was recently shown that co-
engaged IgE is co-internalized [52]. Hence, co-exposure to allergen and specific IgG causes
the removal of IgE from the surface of mast cells.lecular Medicine, April 2020, Vol. 26, No. 4 361
Trends in Molecular Medicine‘Trans-inhibition’, a previously unreported regulatory mechanism by which antibodies can ener-
gize mast cells and basophils when engaging Fc receptors, operates in normal primary mast
cells and basophils, whether of murine or human origin, and human FcγRIIb induces trans-
inhibition similarly to murine FcγRIIb. Trans-inhibition dampened all IgE-induced mast cell secre-
tory responses, including the release of all mediators that account for anaphylaxis. Interestingly,
whereas all ITIM-containing receptors can inhibit activation signals in cis, FcγRIIb, but not other
ITIM-containing receptors, can inhibit signaling in trans [39].
IgG4 antibodies exhibit blocking activity, as might IgG1 antibodies [53]. Thus, the ability of mAbs of
the IgG1 and IgG4 isotypes to neutralize allergens and to engage FcγRIIb should be further investi-
gated. Using recombinantly produced murine antibodies, it was recently shown in mice that IgG1
and IgG2a antibodies of the same specificity were equally potent at inhibiting the allergic reaction [52].
In summary, these observations clearly illustrate the potential of allergen-specific IgG antibodies
to protect against allergic symptoms. While these results do not exclude a potential role for T
cells in SIT, they demonstrate that induction of IgG alone may be sufficient for clinical efficacy.
Thus, it is reasonable to rationalize a next-generation SIT based on the induction of high levels
of IgG antibodies without causing adverse effects of the allergen used for vaccination. We discuss
in the next section how displaying allergens on VLPs enables a repertoire of B cells to be induced
to generate more robust and sustained allergen-specific IgG as a principle effector modality for
next-generation allergy vaccines.
Allergens Displayed on VLPs Induce Strong IgG Responses but Are Unable to
Elicit an Allergic Response
VLPs are multiprotein supramolecular structures with most of the characteristics of viruses other
than they are unable to replicate [54]. Most VLPs have a shell constructed of several identical pro-
tein copies forming icosahedral or helical (rod-shaped) structures [55,56]. There are several VLP-
based vaccines on the market, including vaccines against Hepatitis B, Human Papilloma Virus,
and malaria [54]. The high immunogenicity of VLPs is based on several factors. A key feature of
VLPs is their rigid and repetitive structure, which is a unique feature of viral and bacterial surfaces
and, hence, considered to be a pathogen-associated structural pattern (PASP) [57,58]. Repet-
itive and rigid surfaces are ideal to crosslink B cell receptors and for the recruitment of the innate hu-
moral immune system, in particular natural IgM activating the classical complement cascade [59]. This
is turn increases the deposition of VLPs on follicular dendritic cells, enhancing germinal center forma-
tion in a B cell and complement receptor-dependent fashion [60]. In addition, engaging the comple-
ment receptor CD21 on B cells enhances the formation of long-lived plasma cells [61,62].
Some RNA virus-derived VLPs have an additional seminal feature: they package RNA from the
cellular system that was used for expression. This RNA serves as a ligand for TLR7/8, drives
isotype switching to IgG and IgA [63], and renders IgG responses independent of IL-21 [64]. Fur-
thermore, the presence of RNA drives the generation of secondary plasma cells, which produce
IgG antibodies at increased levels compared with plasma cells generated during primary antibody
responses [65]. Importantly, the potency of the RNA-driven TLR7/8 signals varies with the system
used for expression, with bacterial RNA being superior to eukaryotic RNA [66].
A immunologically optimized VLP platform based on Cucumber Mosaic Virus (CuMV-VLPs) was
recently reported [67]. These plant virus-derived VLPs are produced in Escherichia coli and pack-
age bacterial RNA. Given that Th cell-dependent IgG responses are usually limited by the pres-
ence of Th cells rather than B cells, a universal Th cell epitope derived from tetanus toxin (TT) was
introduced into the VLPs, resulting in CuMVtt. Given that most humans are immunized against TT362 Trends in Molecular Medicine, April 2020, Vol. 26, No. 4
Trends in Molecular Medicineand recognize the universal T cell epitope, this modification is expected to enhance IgG re-
sponses throughout the human population. Importantly, this CuMVtt platform can be used to dis-
play antigens on the VLP surface, usually by chemical conjugation of peptides or proteins. This
renders the conjugated epitopes immunogenic on the underlying VLP surface [67]. Using this
platform, clinically efficacious therapeutic vaccines targeting IL-31 in dogs [68], IL-5 in horses
[69,70], Fel d 1 in cats [71], and pain in mice [72] have been reported. More recently, a vaccine
against peanut allergy based on CuMVtt was developed [47], comprising Ara h 1 or Ara h 2 chem-
ically conjugated to the surface of CuMVtt. A similar technique was used to display recombinant
Fel d 1 on the surface of an RNA phage-derived VLP Qβ [73]. In both cases, allergens displayed
on the VLPs were more immunogenic than their free counterparts. In addition, a Der p 1-derived
antigen also showed strongly enhanced immunogenicity in mice and humans if displayed on
VLPs [74]. More surprisingly, however, while free allergens triggered local and systemic allergic
reactions in vivo and caused basophil activation in vitro, allergens displayed on VLPs failed to
do so. In fact, they completely failed to induce an allergic reaction in vivo and their ability to
cause basophil and mast activation in vitro was attenuated by orders of magnitude, as illustrated
in Figure 3 [73,75]. This was not due to the absence of epitope accessibility on the allergensTrends in Molecular Medicine
Figure 3. Making the Allergen Look Like a Virus Eliminates IgE-Mediated Activation of Mast Cells [75]. (A) Freely
dispersed allergen portrays a more favorable diffusion gradient and is more likely to come into contact with surface-bound
IgE. (B) An allergen displayed on virus-like particles (VLPs) fails to activate mast cells, which can be explained in relation to
the size, geometry, and kinetics of VLPs. (C) Assuming a 40 kDa allergen attached to a 4MDa particle, the diffusion co-
efficient is reduced by a factor of ten, according to the Stoke-Einstein equation, where D is the diffusion constant; μ is the
"mobility", or the ratio of the particle's terminal drift velocity to an applied force, μ = vd/F; kB is Boltzmann's constant; T is
the absolute temperature. Combined with the 60-fold lower effective free concentration of allergen displayed on VLPs, a
process that is driven by diffusion is about 600-fold lower for the VLP-allergen, than for freely dispersed allergen(s).
Trends in Molecular Medicine, April 2020, Vol. 26, No. 4 363
Clinician’s Corner
A crucial goal for SIT is to design and
produce a next-generation immuno-
therapy that has a favourable safety
profile but provides long-term protec-
tion and induction of long-lasting im-
mune responses. The key properties
of viruses that facilitate the induction
of potent immune responses may be
used as the basis for rational vaccine
design.
The VLP-induced B cell response from
preclinical and early clinical studies in
allergy is intriguing and provides a real-
istic aspirational goal as a disease-
modifying treatment.
Food allergy, particularly peanut allergy,
is an area of continued medical need
where the most common approach to
management is strict avoidance, which
is inadequate. Treatment modalities,
such as Oral Immunotherapy,
frequently involve daily administration
and the risk of severe adverse
reactions remains [26].
Safety is the foremost requirement for
any new vaccine in the field of allergy.
The unique and inherent properties of
VLPs allow for controlled presentation of
allergens to the immune system to
enhance vaccine safety, while extending
a broad and cross-reactive protective
umbrella of IgG from memory B cells
not thought possible previously.
Trends in Molecular Medicinedisplayed on VLPs because these allergens were recognized by mAbs and induced allergen-
neutralizing IgG responses in vivo. Interestingly, similar findings have been made for cytokines
displayed on VLPs, which readily induce neutralizing antibodies but do not cause an inflammatory
response [76–78].
There are two explanations for this finding: a physicochemical one and a biochemical one. From a
physicochemical point of view, allergens attached to a VLP are highly concentrated locally. On av-
erage, ~60 allergens are attached to a VLP, reducing the effective free concentration of allergen
by a factor of 60. In addition, they are attached to a 4-MDa particle. According to the Stoke–
Einstein equation, the diffusion coefficient of a molecule is inversely proportional to its size,
which means that, for a 40-kD molecule attached to a 4 MDa particle, the diffusion coefficient
is reduced by a factor of ten. Thus, the effective allergen concentration is reduced by a factor
of ~600 if attached to a VLP [75]. From a biochemical point of view, repetitively displayed allergens
are inefficient at activating mast cells. Indeed, even if allergens on VLPs bind to mast cells, they fail
to trigger cellular activation [75]. Most likely, this is related to the observation that a too high aller-
gen concentration fails to activate mast cells, a phenomenon known as bell-shaped mast cell ac-
tivation, where too much crosslinking appears to be inhibitory. This is different for B cells, which
are optimally activated by repetitive antigens spaced apart by 5–10 nm. The biological explana-
tion for this difference is that B cells are mostly geared to respond to pathogens, which often
are particulate and have a repetitive surface, while mast cells respond to soluble proteins.
Thus, displaying allergens on VLPs greatly enhances their immunogenicity but abrogates their
ability to induce a type I allergic reaction, combining important efficacy and safety features. As
such, this approach provides an attractive option for developing new vaccines in areas of disease,
such as allergy, which may provide an optimal approach to optimizing safety and efficacy.
Induction of IgG Antibodies Against a Single Allergen is Sufficient to Protect
Against a Complex Allergen Cocktail
Use of a single allergen approach, combined with VLPs, has indicated a strong proof of princi-
ple in preclinical models and in humans. For example, a protective effect of allergen-specific
IgG was obtained by the administration of two monoclonal Fel d 1-specific IgG antibodies in
patients with a cat allergy, who showed significantly improved symptoms after nasal stimulation
tests in a placebo-controlled trial [48]. Vaccination with a peptide antigen [derived from the
house dust mite (Der p 1)] covalently coupled to highly repetitive VLPs rapidly induced high
IgG antibody titers in patients [74]. In this study, all individuals showed strongly increased titers
from 14 weeks up to 18 months, while reporting a good safety and tolerability profile, in line with
other VLP-based trials.
More recently, it has been shown in murine models of cat and peanut allergy that the transfer of
allergen-specific IgG resulted protection against local and systemic allergen challenge [34,47],
drawing parallels with those early experiments by Dunbar using antibody-based immunotherapy
[49,50].
The use of a modern VLP nanotechnology platform, optimized for B cell induction using the
Cucumber Mosaic Virus is currently in development, with first-in-human trials plannedi. The pre-
clinical safety and efficacy proof of concept recently reported demonstrated a sufficient titer of IgG
antibodies with adequate affinity and/or avidity for the allergen, and was able to diminish allergic
symptoms after exposure. In this study, a significant increase was observed in specific IgG
responses after combining the Cucumber Mosaic VLP with a single peanut major allergen [47].
Active immunization against a single allergen (Ara h 1 or Ara h 2) resulted in protection against364 Trends in Molecular Medicine, April 2020, Vol. 26, No. 4
Outstanding Questions
Large-scale double-blind, placebo-
controlled trials are needed to under-
stand the translational potential of
allergen-specific VLPs and their clinical
properties, including the contribution
of sustained clinical effect by IgG sub-
classes and their protective umbrella.
In terms of IgG-mediated inhibition of
allergen-induced mast cell activation,
the presence of this receptor on human
basophils iswell characterized. However,
the characterisation of FcγRIIb on human
mast cells is less clear and should be fur-
ther studied.
The prophylactic potential of using VLP-
based vaccination in allergy should be
further tested and assessed in the
clinical setting in individuals who are at
risk of developing allergies.
An adjuvant systems approach using
VLPs with other compatible adjuvants
may optimize clinical outcomes, although
understanding the immunological benefit
and safety profile will be key.
Trends in Molecular Medicinesystemic, local, and oral challenge with peanut extracts, comprising multiple allergens in a sensi-
tized mouse model. Hence, immunization against a single allergen resulted in protection against
the complex allergen challenge [47]. Passive immunization demonstrated that transfer of purified
IgG fractions could confer protection against allergic reactions [47]. This supports the role of IgG
in the mechanism of protection induced by the vaccine candidate (Figure 4). Furthermore, the in-
hibitory receptor FcγRIIb, present on mast cells and basophils ,was critical for reduced allergic
symptoms. These results are in line with previous studies showing that FcγRIIb was able to inhibit
signals generated by activating receptors that were sensitized with non-crossreacting IgE and
were not directly co-engaged with FcγRIIb [34,79].
The VLP-specific B cell response from preclinical and early clinical studies, in the absence of ad-
ditional adjuvants, are of significance. However, VLPs loaded with CpGs have been shown to
provide benefit ,and the combination of VLPs with microadjuvants, such as MCT, has been
shown to confer added benefit through the induction of T cells [80]. Thus, such an approach is
subject to further studies investigating the added benefit in terms of T cell support, with scope
to help further optimize clinical outcomes.
Concluding Remarks
Advances in the study of novel antibody and nanoparticle antigen-carrier designs, such as VLPs,
have renewed interest in the concept of targeting B cells as the primary modality for next-
generation SIT, drawing upon advances in vaccinology. The fact that immunizing against a single
allergen protects against an allergen mixture is striking and could be applied against differentTrends in Molecular Medicine
Figure 4. Inhibition of Mast Cells by FcγRIIb in a Model of Peanut Allergy (Ara h 1). In presence of high levels of IgG
antibodies specific for a single allergen, IgG–immune complexes are formed and bind FcγRIIb, inhibiting all IgE-mediated
signals, including those from IgE molecules crosslinked by other allergens.
Trends in Molecular Medicine, April 2020, Vol. 26, No. 4 365
Trends in Molecular Medicinerelevant allergies that are frequently caused by sensitization against more than one allergen [47].
These advances allow a new platform and approach to allergy treatment that promises to effec-
tively balance safety and efficacy, while providing a well-defined and standardized product. Novel
insights into IgG antibodies as the principle effector modality induced by SIT provide a stronger
footing than ever before, which has already been reflected in promising preclinical and first-
in-human trials, which are now planned to be extended, enabling a deeper understanding of
the translational potential of allergen-specific VLPs and their clinical properties. Large-scale
double-blind, placebo-controlled trials are also needed to understand the translational potential
of allergen-specific VLPs and their clinical properties, including the contribution of sustained
clinical effect by IgG subclasses and their protective umbrella (see Outstanding Questions). An
adjuvant systems approach using VLPs with other compatible adjuvants may optimize clinical
outcomes, but understanding the immunological benefit and safety profile will be key. In terms
of IgG-mediated inhibition of allergen-induced mast cell activation, the presence of this receptor
on human basophils is well characterized, although further studies are required to fully determine
and characterize the presence of FcγRIIb on human mast cells.
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